Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Christine J. Bryson"'
Autor:
Sebastian Spindeldreher, Mark Austin, Carl I. Webster, David C. Lowe, Matthew P. Baker, Tim Jones, Christine J. Bryson, Edward A. Cloake, Anette Karle
Publikováno v:
mAbs
The immunogenicity of clinically administered antibodies has clinical implications for the patients receiving them, ranging from mild consequences, such as increased clearance of the drug from the circulation, to life-threatening effects. The emergen
Publikováno v:
Self/Nonself. 1:314-322
The immunogenicity of protein therapeutics has so far proven to be difficult to predict in patients, with many biologics inducing undesirable immune responses that are directed towards the therapeutic resulting in reduced efficacy, anaphylaxis and oc
Autor:
Wim Jiskoot, Edward A. Cloake, Katie Welch, Matthew P. Baker, Vasco Filipe, Maryam Ahmadi, Stefan Romeijn, Andrea Hawe, Christine J. Bryson, Mark H. Fogg
Publikováno v:
PHARMACEUTICAL RESEARCH, 32(4), 1383-1394
Determine the effect of minute quantities of sub-visible aggregates on the in vitro immunogenicity of clinically relevant protein therapeutics.Monoclonal chimeric (rituximab) and humanized (trastuzumab) antibodies were subjected to fine-tuned stress
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61a67aa6bba85541ee2c6a4092ba2c29
https://hdl.handle.net/1887/38500
https://hdl.handle.net/1887/38500
Autor:
Linda O. Narhi, Marisa K. Joubert, Matthew P. Baker, Jonathan Herskovitz, Michael Moxness, Jane Yang, Meghana Deshpande, Theresa J. Goletz, Lei Zhou, Gregory C. Flynn, Helen M Reynolds, Christine J. Bryson, Vibha Jawa, Mark H. Fogg
Publikováno v:
PLoS ONE
PLoS ONE, Vol 11, Iss 8, p e0159328 (2016)
PLoS ONE, Vol 11, Iss 8, p e0159328 (2016)
An In Vitro Comparative Immunogenicity Assessment (IVCIA) assay was evaluated as a tool for predicting the potential relative immunogenicity of biotherapeutic attributes. Peripheral blood mononuclear cells from up to 50 healthy naïve human donors we
Autor:
Graham Packham, Sopsamorn U. Flavell, Christine J. Bryson, Sarah A. Field, A Noss, David J. Flavell, Sarah L. Warnes
Publikováno v:
British journal of haematology. 134(2)
The chimaeric anti-CD20 antibody rituximab (Rituxan) sensitises lymphoma cells to small molecule cytotoxic drugs and to protein toxins. We have explored the augmentive effect of rituximab on the anti-CD19 immunotoxin BU12-SAPORIN in a model of human